By: Lauren Dembeck
A continuous dosing schedule of PEG-asparaginase (PEGasp) reduced the incidence of hypersensitivity reactions and antibody formation, with no change in efficacy, compared with a noncontinuous schedule in children and adolescents with newly diagnosed acute lymphoblastic leukemia (ALL), according to research published in the Journal of Clinical Oncology.